[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsedrefractory-follicular-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsedrefractory-follicular-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,77,101,123,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100447009","phase-3-a-study-of-zanubrutinib-plus-anti-cd20-versus-lenalidomide-plus-rituximab-in-participants-with-relapsedrefractory-follicular-or-marginal-zone-lymphoma-100447009",false,"NCT05100862","A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed\u002FRefractory Follicular or Marginal Zone Lymphoma","A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed\u002FRefractory Follicular or Marginal Zone Lymphoma","MAHOGANY","Key Inclusion Criteria:\n\n* Histologically confirmed grade 1-3a FL or MZL\n* Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy\n* Need for systemic therapy for FL or MZL\n* Measurable disease by computed tomography or magnetic resonance imaging\n* Adequate bone marrow, liver and renal function\n\nKey Exclusion Criteria:\n\n* Transformation to aggressive lymphoma\n* Requiring ongoing need for corticosteroid treatment\n* Clinically significant cardiovascular disease\n* Prior malignancy within the past 2 years\n* Active fungal, bacterial, and\u002For viral infection that requires systemic therapy\n* Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\\\u003C 24 months)\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":20,"type":21},780,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\\^2) in participants with relapsed\u002Frefractory (R\u002FR) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET\u002FCT), and to compare the efficacy of zanubrutinib plus rituximab versus R\\^2 in participants with R\u002FR marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.",[27,28],"Relapsed\u002FRefractory Follicular Lymphoma","Marginal Zone Lymphoma",[30,31,32,33,34],"Zanubrutinib","BGB-3111","Rituximab","Lenalidomide","Obinutuzumab","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2022-03-10",{"date":43,"type":21},"2030-06",{"name":45,"class":46},"BeOne Medicines","INDUSTRY",277,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100527555","phase-3-a-trial-to-find-out-if-odronextamab-combined-with-lenalidomide-is-safe-and-works-better-than-rituximab-combined-with-lenalidomide-in-adult-participants-with-follicular-lymphoma-and-marginal-zone-lymphoma-100527555","NCT06149286","A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed\u002FRefractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)","OLYMPIA-5","Key Inclusion Criteria:\n\n1. Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.\n2. Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody and participant should meet indication for treatment, as described in the protocol.\n3. Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography \\[CT\\], or Magnetic Resonance Imaging \\[MRI\\] imaging, as described in the protocol.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n5. Adequate hematologic and organ function, as described in the protocol.\n6. All study participants must:\n\n   1. Have an understanding that lenalidomide could have a potential teratogenic risk.\n   2. Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.\n   3. Agree not to share study medication with another person.\n   4. Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.\n\nKey Exclusion Criteria:\n\n1. Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.\n2. Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.\n3. History of or current relevant CNS pathology, as described in the protocol.\n4. A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.\n5. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.\n6. Allergy\u002Fhypersensitivity to study drugs or excipients. as described in the protocol.\n7. Active infection as defined in the protocol.\n\nNote: Other protocol-defined Inclusion\u002FExclusion criteria apply",{"count":57,"type":21},470,[24],"This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called \"relapsed\"), or did not respond to treatment (called \"refractory\"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).\n\nThis study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).\n\nThe aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered \"first-in-human\" as it has not been tested as a combination treatment in humans before.\n\nThe aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called \"the comparator drug\") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed\u002Frefractory FL and\u002For MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug in combination with lenalidomide\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)\n* The impact from the study drug on quality-of-life and ability to complete routine daily activities",[27,61],"Relapsed\u002FRefractory Marginal Zone Lymphoma (R\u002FR MZL)",[27,63,64,65,66],"Relapsed\u002FRefractory Marginal Zone Lymphoma","Non-Hodgkin lymphomas","Indolent lymphomas","Odronextamab","2026-05-05",{"date":69,"type":39},"2026-05-06",{"date":71,"type":39},"2023-12-28",{"date":73,"type":21},"2029-01-23",{"name":75,"class":46},"Regeneron Pharmaceuticals",169,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100625096","phase-2-efficacy-and-safety-of-zanubrutinib-rituximab-and-lenalidomide-zr-in-combination-with-tislelizumab-for-relapsedrefractory-follicular-lymphoma-100625096","NCT07418190","Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\n* Eligible participants must meet all of the following criteria:\n\nProvide written informed consent. Age ≥18 years . Histologically confirmed relapsed\u002Frefractory follicular lymphoma (R\u002FR FL) . Received at least two prior lines of systemic therapy , including anti-CD20 monoclonal antibody therapy.\n\nECOG performance status 0-1 . Measurable disease , with longest diameter \\>1.5 cm . Estimated life expectancy (per investigator assessment) ≥18 weeks . Adverse events from prior anticancer therapy must have resolved to ≤ grade 1 (except alopecia and anorexia).\n\nAdequate hepatic function:\n\nTotal bilirubin ≤1.5 × ULN ; for patients with documented Gilbert syndrome: total bilirubin ≤3 × ULN with predominantly indirect hyperbilirubinemia.\n\nAST and ALT ≤3 × ULN .\n\nAdequate hematologic function:\n\nANC ≥1.5 × 10⁹\u002FL (≥1,500\u002FµL) Platelets ≥75,000\u002FµL , with no platelet transfusion within 14 days prior to first dosing on Cycle 1 Day 1 Hemoglobin ≥10.0 g\u002FdL (6.2 mmol\u002FL), with no blood transfusion within 21 days prior to first dosing on Cycle 1 Day 1 Adequate renal function: serum creatinine ≤1.5 × ULN , or creatinine clearance ≥50 mL\u002Fmin calculated by the Cockcroft-Gault formula (see Appendix 14), for patients in whom serum creatinine may not adequately reflect renal function per investigator judgment.\n\nFor women of childbearing potential: negative serum pregnancy test within 7 days before study treatment; postmenopausal women (non-treatment-related amenorrhea ≥12 months) or surgically sterile women (no ovaries and\u002For uterus) are exempt. Women of childbearing potential must agree to abstinence (avoid heterosexual intercourse) or to use effective contraception.\n\nFor men: agree to abstinence (avoid heterosexual intercourse) or to use effective contraception.\n\nExclusion Criteria:\n\n* Participants meeting any of the following will be excluded:\n\n  1. Unable to comply with protocol-required hospitalization and restrictions.\n  2. Active infection or latent tuberculosis infection.\n  3. History of severe hypersensitivity to drugs of the same class.\n  4. Current central nervous system involvement.\n  5. Pregnant or breastfeeding women.\n  6. Uncontrolled comorbidities (e.g., cardiac disease, immune disorders); myocardial infarction, unstable arrhythmia, or unstable angina within the past 6 months.\n  7. Illicit drug use or alcohol abuse within 12 months prior to screening, per investigator judgment.\n  8. Any other disease, metabolic disorder, physical examination finding, or clinical laboratory abnormality that reasonably suggests a contraindication to the investigational products.\n  9. The investigator should review vaccination status of potential participants and, prior to study initiation, follow local disease control and prevention guidelines for adult immunization with non-live vaccines aimed at preventing infectious diseases.\n  10. Any psychiatric or cognitive disorder that may limit understanding\u002Fexecution of informed consent or protocol compliance.\n  11. Pregnant or breastfeeding women, or women\u002Fmen (or male partners) planning pregnancy during the study period.\n  12. Any other condition deemed by the investigator to make the participant unsuitable for the trial.\n\n      * Cases to Be Excluded From Statistical Analysis (per protocol)\n\nParticipants already enrolled who meet any of the following will be treated as excluded cases in statistical analyses:\n\nPost-enrollment discovery of non-fulfillment of eligibility criteria. Prior exposure to zanubrutinib or other BTK inhibitors. Intolerable toxicity after taking zanubrutinib or other BTK inhibitors. Received fewer than two consecutive administrations after enrollment such that objective efficacy cannot be assessed (adverse events may still be assessable).\n\nProtocol violations. Prior hematopoietic stem cell transplantation.","75 Years",{"count":85,"type":21},33,[87],"PHASE2","This is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of zanubrutinib, rituximab, and lenalidomide (ZR²) in combination with tislelizumab in patients with relapsed\u002Frefractory follicular lymphoma who have relapsed or are refractory after ≥1 prior systemic therapy.\n\nAfter successful screening, enrolled patients will receive 6 treatment cycles (21 days per cycle). Disease response will be assessed by CT\u002FPET-CT during treatment and after completion of induction. Patients who achieve CR\u002FPR\u002FSD will proceed to the maintenance phase; patients who do not achieve at least SD (i.e., fail to reach CR\u002FPR\u002FSD) during induction will discontinue the study. Patients with CR\u002FPR\u002FSD after induction will receive maintenance therapy with zanubrutinib plus tislelizumab until disease progression, unacceptable toxicity, or completion of 1 year of maintenance.\n\nEfficacy and safety assessments will be performed per protocol. Tumor response will be assessed by site investigators according to the 2014 Lugano criteria, including determination of response status, date of response, and date of progression\u002Frelapse.",[27],"2026-02-11",{"date":92,"type":39},"2026-02-18",{"date":94,"type":21},"2026-02-01",{"date":96,"type":21},"2029-12-31",{"name":98,"class":99},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":100},"100614386","study-to-evaluate-the-response-to-treatment-with-mosunetuzumab-in-relapsedrefractory-follicular-lymphoma-fl-after-at-least-two-lines-of-therapy-within-the-compassionate-use-program-cup-100614386","NCT07278921","Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed\u002FRefractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).","Retrospective, Multicenter Observational Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed\u002FRefractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).","MosuOSSHSR","Inclusion Criteria:\n\n* Adult patients (\\>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.\n* Patients who have signed informed consent for treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patients with other types of cancer\u002Flymphoma\n* Patients not eligible for the Mosunetuzumab compassionate use program",{"count":110,"type":21},25,"OBSERVATIONAL","Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed\u002Frefractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).",[27],"2026-01-30",{"date":116,"type":39},"2026-02-03",{"date":118,"type":39},"2025-12-01",{"date":120,"type":21},"2026-12-31",{"name":122,"class":99},"Andrés José Maria Ferreri",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":100},"100620258","phase-3-imm0306-in-combination-with-lenalidomide-vs-placebo-in-combination-with-lenalidomide-in-patients-with-relapsedrefractory-follicular-lymphoma-100620258","NCT07355283","IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed\u002FRefractory Follicular Lymphoma","A Randomized, Double-Blind, Controlled, Multicenter, Phase III Clinical Study of IMM0306 (Amulirafusp Alfa) for Injection in Combination With Lenalidomide Versus Placebo in Combination With Lenalidomide in Patients With Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n2. At least one measurable lesion (as per Lugano 2014 criteria).\n3. Histologically confirmed CD20-positive Follicular Lymphoma, Grade 1, 2, or 3a.\n4. Previously received at least two prior systemic regimens, including at least one line containing an anti-CD20 monoclonal antibody.\n5. Adequate hepatic, hematologic, and renal function.\n6. Expected survival at least 6 months.\n\nExclusion Criteria:\n\n1. Autologous HSCT within 100 days prior to first administration, or any prior allogeneic HSCT or solid organ transplantation.\n2. History of central nervous system (CNS) metastases or active CNS involvement.\n3. History of other malignancy within the past 5 years.\n4. Severe organic cardiovascular or cerebrovascular diseases.\n5. History of severe allergic reactions to any components of the trial drug, any macromolecular protein preparations or monoclonal antibodies.\n6. Previous treatment with anti-CD47 monoclonal antibody\u002FSIRPα fusion protein.\n7. Human immunodeficiency virus (HIV) infection.\n8. Echocardiography examination indicating left ventricular ejection fraction (LVEF) \\\u003C 55%.\n9. Active infection requiring systemic therapy (e.g., fungal, bacterial, viral).",{"count":131,"type":21},198,[24],"This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in patients with Relapsed\u002FRefractory Follicular lymphoma. Primary endpoints are Complete Remission Rate (CRR) and Progression-Free Survival (PFS).",[27],"NOT_YET_RECRUITING","2026-01-25",{"date":138,"type":39},"2026-01-27",{"date":140,"type":21},"2026-02",{"date":142,"type":21},"2030-10",{"name":144,"class":99},"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100595380","phase-2-a-multicenter-single-arm-open-label-phase-ii-trial-of-mosunetuzumab-in-combination-with-tislelizumab-for-rr-fl-100595380","NCT07031700","A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r\u002Fr FL","A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for Relapsed\u002FRefractory Follicular Lymphoma (r\u002Fr FL)","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Age ≥18 years.\n3. Histologically confirmed relapsed\u002Frefractory follicular lymphoma (r\u002Fr FL).\n4. Received at least two prior systemic therapies, including anti-CD20 monoclonal antibody therapy.\n5. ECOG performance status 0-1.\n6. Expected survival ≥12 weeks.\n7. Measurable disease (longest diameter \\>1.5 cm).\n8. Adequate organ function:\n\n   * Hepatic function: Total bilirubin ≤1.5×ULN; AST\u002FALT ≤3×ULN.\n   * Hematologic function: ANC ≥1.5 × 10⁹\u002FL; Platelets ≥75,000\u002FμL; Hemoglobin ≥10.0 g\u002FdL.\n   * Renal function: Serum creatinine ≤1.5×ULN or CrCl ≥50 mL\u002Fmin (Cockcroft-Gault formula).\n9. Women of childbearing potential must have a negative serum pregnancy test and agree to use contraception.\n\nExclusion Criteria:\n\n1. Inability to comply with study hospitalization and restrictions.\n2. Active infections (including tuberculosis) or immunocompromised status.\n3. Prior history of severe hypersensitivity to similar agents.\n4. CNS involvement of lymphoma.\n5. Pregnant or breastfeeding women.\n6. Uncontrolled comorbid conditions, including cardiovascular or autoimmune diseases.\n7. Receipt of live attenuated vaccines within 4 weeks before enrollment.\n8. Use of systemic immunosuppressants within 2 weeks prior to first dose.\n9. History of drug or alcohol abuse in the past 12 months.\n10. Any condition deemed inappropriate for study participation by the investigator.",{"count":153,"type":21},22,[87],"This is a multicenter, single-arm, open-label, investigator-initiated, phase II clinical trial designed to evaluate the feasibility, efficacy, and safety of Mosunetuzumab in combination with Tislelizumab in patients with relapsed\u002Frefractory follicular lymphoma (r\u002Fr FL).",[27],"2025-06-12",{"date":159,"type":39},"2025-06-22",{"date":161,"type":21},"2025-07-01",{"date":163,"type":21},"2027-07-30",{"name":165,"class":99},"Tianjin Medical University Cancer Institute and Hospital"]